Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

Recombinant Cytokeratin 14 (KRT14) (Squamous Cell Marker) Antibody [KRT14/7054R]

In Stock
Catalog Number Formulation Size Price
3861-RBM26-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$229.00
3861-RBM26-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$519.00
3861-RBM26-P1ABX
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
100ug
$519.00
Flat Rate Domestic: $60 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol Note
Immunohistochemistry (IHC)
1-2ug/ml
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes
Western Blot (WB)
2-4ug/ml

Summary

Cytokeratin 14 is a member of the type I keratin family of intermediate filament proteins. It always pairs with the type II keratin K5 and form the primary keratin pair of the keratinocytes of stratified squamous epithelia, including the epidermis as well as mucosal non-keratinizing stratified squamous epithelia.Cytokeratin 14 is strongly expressed in the undifferentiated basal cell layer containing the stem cells and are down-regulated in the differentiating suprabasal cell layers. Otherwise, in the widely well stratified follicular outer root sheath, cytokeratin 14 is uniformly expressed throughout all layers. The expression spectrum of cytokeratin 14 in tumors corresponds well to the patterns in normal epithelia. Thus, most squamous cell carcinomas as well as malignant mesotheliomas strongly express this keratin whereas little, focal, or no expression is found in adenocarcinomas.Cytokeratin 14 may be a useful marker in the differential diagnosis of squamous cell carcinoma from other epithelial tumors. Recent studies also indicate that CK14 expression in breast cancer corresponded with poor clinical outcome and that CK14 may have diagnostic value in the sub-classification of NSCLC.

Product Properties & Targets

Host
Rabbit
Species Reactivity
Isotype / Light Chain
IgG / Kappa
Cellular Localization
Cytoplasm.
Gene Name
Positive Control
A431 or HeLa cells. Human prostate|skin or squamous cell carcinoma.
Immunogen
Recombinant human KRT14 fragment (around aa350-472) (exact sequence is proprietary)
Alternate Names
Keratin, type I cytoskeletal 14, Cytokeratin-14, Keratin-14, CK-14; Dowling Meara; ebs3; ebs4; Epidermolysis Bullosa Simplex; k14; Keratin 14; Keratin Type I Cytoskeletal 14; Koebner; krt14; NFJ

Database Links

Entrez Gene ID
SwissProt

Additional Information

Clone
KRT14/7054R
Chromosome Location
17q21.2
Mol. Weight of Antigen
50kDa

Functions

  • The nonhelical tail domain is involved in promoting KRT5-KRT14 filaments to self-organize into large bundles and enhances the mechanical properties involved in resilience of keratin intermediate filaments in vitro.

Key References

  • Reis-Filho JS, et.al. Virchows Arch. 2003 Aug;443(2):122-32.

PubMed Links

Storage & Stability

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Reviews

There are no reviews yet.

Be the first to review “Recombinant Cytokeratin 14 (KRT14) (Squamous Cell Marker) Antibody”

Your email address will not be published. Required fields are marked *

PARTNERSHIP OPPORTUNITIES

We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK